CN112584841A8 - 肿瘤减小制剂及其使用方法 - Google Patents

肿瘤减小制剂及其使用方法 Download PDF

Info

Publication number
CN112584841A8
CN112584841A8 CN201980054337.1A CN201980054337A CN112584841A8 CN 112584841 A8 CN112584841 A8 CN 112584841A8 CN 201980054337 A CN201980054337 A CN 201980054337A CN 112584841 A8 CN112584841 A8 CN 112584841A8
Authority
CN
China
Prior art keywords
methods
tumor reduction
formulations
reduction formulations
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980054337.1A
Other languages
English (en)
Other versions
CN112584841A (zh
Inventor
史蒂文·霍夫曼
约翰·罗思曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dimei
Original Assignee
Dimei
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dimei filed Critical Dimei
Publication of CN112584841A publication Critical patent/CN112584841A/zh
Publication of CN112584841A8 publication Critical patent/CN112584841A8/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

本发明涉及肿瘤减小组合物及其方法。特别地，本发明涉及包含硬化剂与渗透剂之组合的组合物。
CN201980054337.1A 2018-07-09 2019-07-02 肿瘤减小制剂及其使用方法 Pending CN112584841A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862695613P 2018-07-09 2018-07-09
US62/695,614 2018-07-09
US62/695,613 2018-07-09
PCT/US2019/040264 WO2020023191A1 (en) 2018-07-09 2019-07-02 Tumor reduction formulations and methods of use thereof

Publications (2)

Publication Number Publication Date
CN112584841A CN112584841A (zh) 2021-03-30
CN112584841A8 true CN112584841A8 (zh) 2021-06-18

Family

ID=75267393

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980054337.1A Pending CN112584841A (zh) 2018-07-09 2019-07-02 肿瘤减小制剂及其使用方法

Country Status (11)

Country Link
EP (1) EP3820482A4 (zh)
JP (1) JP2021530482A (zh)
KR (1) KR20220098082A (zh)
CN (1) CN112584841A (zh)
AU (1) AU2019309757A1 (zh)
BR (1) BR112021000279A8 (zh)
CA (1) CA3105717A1 (zh)
EA (1) EA202190201A1 (zh)
IL (1) IL280000A (zh)
PH (1) PH12021550033A1 (zh)
WO (1) WO2020023191A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11534420B2 (en) 2019-05-14 2022-12-27 Tyme, Inc. Compositions and methods for treating cancer
JP2023505689A (ja) * 2019-12-09 2023-02-10 タイム，インコーポレーテッド 医薬組成物および方法
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0507308A (pt) * 2004-01-29 2007-06-26 Baxter Int nanossuspensões de agentes anti-retrovirais para entrega ao sistema nervoso central aumentada
WO2006099685A1 (en) * 2005-03-24 2006-09-28 Medical Therapies Limited Method for the prophylaxis or treatment of carcinomas
CN101023940A (zh) * 2006-02-20 2007-08-29 郝守祝 一种紫杉烷类化合物的药用组合物、制备方法及用途
WO2016007741A1 (en) * 2014-07-11 2016-01-14 The Regents Of The University Of California Tumor selective macropinocytosis-dependent rapidly internalizing antibodies
US9687528B2 (en) * 2014-12-23 2017-06-27 Steven Hoffman Transdermal formulations
US20190091252A1 (en) * 2016-03-15 2019-03-28 Tyme, Inc. Pharmaceutical compositions for the treatment of cancer

Also Published As

Publication number Publication date
EP3820482A1 (en) 2021-05-19
IL280000A (en) 2021-03-01
AU2019309757A1 (en) 2021-03-04
KR20220098082A (ko) 2022-07-11
CN112584841A (zh) 2021-03-30
BR112021000279A2 (pt) 2021-04-06
JP2021530482A (ja) 2021-11-11
PH12021550033A1 (en) 2021-09-20
EA202190201A1 (ru) 2021-04-09
CA3105717A1 (en) 2020-01-30
EP3820482A4 (en) 2022-03-23
WO2020023191A1 (en) 2020-01-30
BR112021000279A8 (pt) 2021-04-20

Similar Documents

Publication Publication Date Title
WO2021217004A3 (en) Methods and compositions for treating virus-associated inflammation
CA3148745A1 (en) Kras g12d inhibitors
WO2019032662A8 (en) Clec9a binding agents and use thereof
WO2017173415A3 (en) Saccharide-polypeptide conjugate compositions and methods of use thereof
WO2017062862A3 (en) Oligonucleotide compositions and methods thereof
CN112584841A8 (zh) 肿瘤减小制剂及其使用方法
EP3898797A4 (en) EXPANSION AGENT COMPOSITIONS CONTAINING 1,2,2-TRIFLUORO-1-TRIFLUOROMETHYLCYCLOBUTANE, AND METHODS OF EXPANSION
IL291760A (en) Aminobenzazepine, amide-linked immunoconjugates and uses thereof
WO2019120234A3 (zh) 作为溴结构域蛋白质抑制剂的化合物和组合物
EP3894398A4 (en) 3,3-DIFLUORALLYLAMINES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREOF
IL290339A (en) Preparations for local administration containing cannabidiol, a method for their preparation and their use
WO2017155906A8 (en) Long lasting cosmetic compositions
WO2017069822A3 (en) Shear-thinning compositions as an intravascular embolic agent
MX2019006091A (es) Composicion de champu en seco.
IL289997A (en) Fungicidal combinations, mixtures and preparations and their uses
SG11201908281VA (en) Phenalene-1-one-containing photosensitizer composition, phenalene-1-one compound and the use thereof
MX2020013170A (es) Composicion agricola.
WO2019043176A3 (en) HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY
WO2017019721A3 (en) Combinations of ezh2 inhibitors with further agents for use in the treatment of cancer
EP3646855A4 (en) COMPOSITION FOR SOLID PREPARATION FOR ORAL USE INCLUDING A PROTON PUMP INHIBITOR, SOLID PREPARATION FOR ORAL USE INCLUDING IT, AND PROCESS FOR PREPARATION
WO2017075171A3 (en) Pamam dendrimer based cest imaging agents and uses thereof
IL290331A (en) RNA-directing ligands, preparations containing them, and methods for their preparation and use
EP3790552A4 (en) COMBINATION COMPOSITIONS WITH BISFLUORAKYL-1,4-BENZODIAZEPINONE COMPOUNDS AND METHODS OF USE THERE
WO2019200314A3 (en) Hinokitiol analogues, methods of preparing and pharmaceutical compositions thereof
MX2021000314A (es) Formulaciones reductoras de tumores y metodos de uso de las mismas.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CI02 Correction of invention patent application
CI02 Correction of invention patent application

Correction item: Priority

Correct: 62/695,613 2018.07.09 US

False: 62/695,614 2018.07.09 US

Number: 14-01

Volume: 37

Correction item: Priority

Correct: 62/695,613 2018.07.09 US

False: 62/695,614 2018.07.09 US

Number: 14-01

Page: The title page

Volume: 37